Skip to main content
OpenTrials
Completed

NCT Number: NCT06408038

Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer

A prospective, single-centre, proof-of-concept pilot study in patients with metastatic breast cancers (MBC) (whatever the immunohistochemical subtype) treated at the IUCT-O. Eligible patients will be selected and informed of this study during a medical consultation for cancer that has metastasised, has relapsed or is progressing metastatically, by medical oncologists at the Oncopole Claudius Regaud (OCR). Then, with the patient's agreement and before the start of anti-tumour treatment, a blood sample will be taken to detect DP-circulating cells. A breast cancer tumour sample (non-bone metastasis or, failing that, primary tumour) must be available (FFPE archived tumour block).

Each patient will participate in the study for one day.

60 patients will be included in this interventional study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

IUCT-O

Toulouse, 31059, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with metastatic breast cancer eligible for 1st, 2nd or 3rd line treatment at stage IV, regardless of immunohistochemical subtype (triple-negative, RH+/HER2-negative or HER2-positive).
  • Patient with metastatic disease or metastatic relapse or progression who has not yet started 1st line treatment for metastatic disease or line 2 or line 3.
  • Tumour sample available (archived tumour block): non-bone metastasis preferred if available or, failing this, primary breast tumour.
  • Age ≥ 18 years and WHO ≤ 2.
  • Patient affiliated to a French Social Security scheme.
  • Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study.

Exclusion criteria

  • Associated pathology(ies) likely to prevent the study procedure from running smoothly.
  • Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
  • Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
  • Patient who has presented with another solid tumour (excluding carcinoma in situ of the breast or cervix) within 5 years.
  • Pregnant patient.

Treatment and study plan

For each patient included, the samples described below will be collected:

Other
  • A single blood sample will be taken before initiation of the metastatic treatment line. The volume of total blood sampled is 34mL.
  • A tumour sample (FFPE block already archived) from a metastasis (other than bone) if available or, failing this, from the primary breast tumour, will be sent to the sponsor in order to meet the objectives of the study.

Once the blood sample has been taken, patients will have completed their participation in the study.

Primary outcomes

  1. Rate of patients with proven tumour origin of DP-circulating cells. This is defined as the number of patients with proven tumour origin of DP-circulating cells out of the number of patients with DP-circulating cells.

    Time frame: Approximately 16 months after the start of the study

Secondary outcomes

  1. The presence and number of DP-circulating cells and conventional circulating tumor cells (CTCs).

    Time frame: Approximately 16 months after the start of the study

    The heterogeneity of DP-circulating cells will be estimated by the penetrance of genomic alterations in a given patient, which will give us information on the sub-clonality of the alteration (shared by x percent of cells), but also by single cell DNA sequencing (scDNAseq).

Sponsors and collaborators

Lead sponsor

Institut Claudius Regaud

Other

Collaborators

  • Fondation Toulouse Cancer Santé

Registry information

Acronym: DP METABREAST

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 9, 2024
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.